학술논문
Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Document Type
Article
Author
Garcia-Marco, Jose; Baltasar Tello, Patricia; Garcia, Esther González; Ríos Herranz, Eduardo; Ramirez Payer, Angel; Terol Castera, María José; Champ, Diana; Medina Perez, Angeles; Gironella, Mercedes; Rodríguez Fernández, Alicia; Muntañola Prat, Ana; Suárez Cabrera, Alexia; Jurado Chacón, Manuel; Fernández Zarzoso, Miguel; Rodríguez, Mercedes; Clavel, Juana; Dourdil Sahun, Maria Victoria; Ferra Coll, Christelle M; Pérez Persona, Ernesto; Marrero Santos, Carmen Milagros; Forés, Rafael; Delgado, Julio
Source
Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p4321-4321, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Introduction:The use of combined rituximab (R)-bendamustine(B) has shown to be effective in terms of overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) in pts with relapsed/refractory CLL. Based on the enhanced in vitro and in vivo anti-CLL activity of obinutuzumab compared to rituximab, we designed this phase II study to evaluate the efficacy of obinutuzumab(Obi) with B in patients (pts) with relapsed or refractory CLL.